Odylia Therapeutics will be discussing our RPGRIP1 Gene Therapy program to treat vision loss in patients diagnosed with Leber Congenital Amaurosis 6 (LCA6). Join us to learn more about Odylia Therapeutics and the progress of our gene therapy program, as well as next steps. Meeting details: Tuesday,...

Atlanta, GA August 6, 2019 – Emil Kakkis, MD, PhD, joins the Board of Directors for Odylia Therapeutics.  Kakkis is the CEO, President and Founder of Ultragenyx Pharmaceutical Inc., which is committed to developing and commercializing treatments  for multiple rare and ultra-rare diseases. He brings to Odylia vast knowledge...